Bio­gen comes un­der re­newed fire as a lead­ing Alzheimer's ex­pert rais­es se­ri­ous ques­tions about the ad­u­canum­ab da­ta

Bio­gen ex­ecs have lots of ex­plain­ing to do lat­er this week if they ex­pect to hold on to the mas­sive up­swing in mar­ket cap $BI­IB the big biotech ex­pe­ri­enced with their up­beat as­sess­ment of their chances of win­ning an FDA ap­proval of ad­u­canum­ab as the first dis­ease-mod­i­fy­ing ther­a­py for Alzheimer’s — wide­ly con­sid­ered the gold­en tick­et in R&D to­day for a megablock­buster mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER